selection

pharmaceutical industry

This tag is associated with 8 posts

Coronavirus vaccines strategy

On 17 June 2020, the European Commission presented a strategy to accelerate the development, manufacturing and deployment of vaccines against the coronavirus disease (Covid-19). Continue reading

A pharmaceutical strategy for Europe: First steps

On 1 June 2020, the European Commission published a roadmap for a pharmaceutical strategy for Europe. The strategy will have the overall goal of ensuring Europe’s supply of safe and affordable medicines and supporting the European pharmaceutical industry’s innovation efforts. Continue reading

Addressing shortages of medicines [Policy Podcast]

Medicines shortages have been a growing problem in the European Union (EU) in recent years. As the coronavirus outbreak unfolds, the risk of bottlenecks in the supply of medicines to patients has become particularly high. Continue reading

EU imports and exports of medical equipment [Policy Podcast]

The crisis caused by the coronavirus pandemic has, with tragic consequences, brought to the fore the fact that the European Union (EU) is dependent on non-EU sources for medical equipment such as personal protection equipment (including masks) and artificial respiratory equipment, as well as other products needed in the fight against the virus. Continue reading

‘Mind the gap’ between drug development and clinical practice

For a drug to be prescribed to a patient, it must first be rigorously tested for efficacy and safety and subsequently be approved by relevant authoritative bodies, such as the European Medicines Agency (EMA). Continue reading

European Parliament Plenary Session – April II 2019

Unsurprisingly, the agenda for this final plenary session of Parliament’s 2014-2019 term will deal with a range of issues that are emblematic of the major themes that have marked this eighth legislature. Continue reading

Therapies for the future – Advanced therapies & nanomedicine

Advanced therapy medicinal products constitute a heterogeneous group of biopharmaceuticals encompassing gene therapy and somatic cell therapy medicinal products, as well as tissue-engineered and combined products (tissues or cells associated with a device). Continue reading

Therapies for the future – Exploring the potential of innovative treatments in Europe

The purpose of this workshop is to report on the status of nanomaterial-based and advanced therapy medicinal products, as well as on possible pathways for the future development of these new therapies in Europe. Continue reading

Download the EPRS App

EPRS App on Google Play
EPRS App on App Store
What Europe Does For You
EU Legislation in Progress
Topical Digests
EPRS Podcasts

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 3,390 other followers

Disclaimer and Copyright statement

The content of all documents (and articles) contained in this blog is the sole responsibility of the author and any opinions expressed therein do not necessarily represent the official position of the European Parliament. It is addressed to the Members and staff of the EP for their parliamentary work. Reproduction and translation for non-commercial purposes are authorised, provided the source is acknowledged and the European Parliament is given prior notice and sent a copy.

For a comprehensive description of our cookie and data protection policies, please visit Terms and Conditions page.

Copyright © European Union, 2014-2019. All rights reserved.